Franklin Street Advisors Inc. NC Acquires 8,191 Shares of Bristol-Myers Squibb (NYSE:BMY)

Franklin Street Advisors Inc. NC grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 355,593 shares of the biopharmaceutical company's stock after purchasing an additional 8,191 shares during the period. Bristol-Myers Squibb makes up 1.5% of Franklin Street Advisors Inc. NC's portfolio, making the stock its 23rd biggest holding. Franklin Street Advisors Inc. NC's holdings in Bristol-Myers Squibb were worth $21,688,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BMY. Norges Bank acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $1,989,525,000. Ameriprise Financial Inc. boosted its holdings in shares of Bristol-Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Bristol-Myers Squibb by 701.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after purchasing an additional 10,913,708 shares in the last quarter. Wellington Management Group LLP increased its stake in Bristol-Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after buying an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $257,618,000. 76.41% of the stock is currently owned by institutional investors.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Down 1.9%

NYSE BMY traded down $0.99 on Friday, hitting $49.71. 9,394,854 shares of the company were exchanged, compared to its average volume of 13,016,655. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market cap of $101.15 billion, a PE ratio of -11.25, a PEG ratio of 2.07 and a beta of 0.38. The stock has a fifty day moving average of $48.78 and a 200-day moving average of $54.83. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the previous year, the business posted ($4.40) EPS. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. As a group, analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BMY. UBS Group reduced their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Piper Sandler assumed coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.